Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

NCT03932331 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03932331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03932331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 29, 2020
Completion date
June 24, 2026
Enrollment
105 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

phase i: relapsed or refractory b-cell malignancies, phase ii cohort a: relapsed or refractory mantle cell lymphoma, phase ii cohort b: relapsed or refractory chronic lymphocytic leukemia